Humana price target lowered to $250 from $380 at UBS

UBS lowered the firm’s price target on Humana to $250 from $380 and keeps a Neutral rating on the shares following the reported decline in the 2025 Star ratings for payment year 2026. UBS believes the company’s performance will largely depend on whether or not they are successful in their appeal with CMS, but notes that it is “unlikely” that an answer will be available by the start of open enrollment, the analyst tells investors in a research note.